# Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

> **NCT03005002** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Carcinoma in the Liver
- MLH1 Gene Mutation
- MSH6 Gene Mutation
- PMS2 Gene Mutation
- Stage IV Colorectal Cancer
- Stage IVA Colorectal Cancer
- Stage IVB Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT03005002
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2019-11-26
- **Final completion:** 2019-11-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005002, "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03005002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*